Browse studies

Find your next paid study

6 recruiting studies matching your filters

A Phase 1, Open-Label, Dose-Escalation and Expansion Study of AGX101, a TM4SF1 Directed Antibody Drug Conjugate in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors

AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various …

CancerAdvanced CancerLocally Advanced Carcinoma+8 more

Estimated

~$10 – $8,750

Angiex, Inc.NCT06440005

Phase 2

An Open-Label, Multicenter, Phase 2 Study With Safety Lead-In of Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab in Patients With Angiosarcoma

This is a multicenter, open-label study of Intratumoral Vusolimogene Oderparepvec (VO) to investigate safety and estimate when used in combination with pembrol…

AngiosarcomaAngiosarcoma, Adult

Estimated

~$10 – $7,500

Varun Monga, MBBSNCT06898970

Phase 2

Pilot Study of Ivonescimab in Advanced/Metastatic Cutaneous Angiosarcoma

This is a pilot study evaluating the efficacy and safety of ivonescimab in subjects with advanced or metastatic cutaneous angiosarcoma who have previously been…

Cutaneous Angiosarcoma

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07655570

Phase 1

A First-In-Human Phase I, Open Label, Safety and Tolerability Study of Escalating Multiple Doses of Intratumoral MQ710, a Multi-Transgene Expressing Modified Vaccinia Virus Ankara-Based Virotherapy, Alone and in Combination With the Systemic Checkpoint Inhibitor Pembrolizumab in Solid Tumors

Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (ad…

Cutaneous Squamous Cell CarcinomaSCC - Squamous Cell CarcinomaBasal Cell Carcinoma+16 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer Center

Phase 1

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk * To estimate the 3-year event-free surviva…

Adipocytic NeoplasmLiposarcomaAtypical Fibroxanthoma+39 more

Phase 2

I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which t…

Breast NeoplasmsBreast CancerBreast Tumors+8 more

Estimated

~$10 – $7,500

QuantumLeap Healthcare CollaborativeNCT01042379